Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects

详细信息    查看全文

• 作者：Andreas G. Franke ; Christiana Bagusat…
• 关键词：Pharmacological cognitive enhancement ; Stimulant(s) ; Prescriptive drug(s) ; Over ; the ; counter ; drug(s)
• 刊名：European Archives of Psychiatry and Clinical Neuroscience
• 出版年：2014
• 出版时间：November 2014
• 年：2014
• 卷：264
• 期：1-supp
• 页码：83-90
• 全文大小：192 KB
• 参考文献：1. Bagot, KS, Kaminer, Y (2014) Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction 109: pp. 547-557 CrossRef
  2. Benowitz, NL (1990) Clinical pharmacology of caffeine. Annu Rev Med 41: pp. 277-288 CrossRef
  3. Birks J, Grimley Evans J (2009) Ginkgo biloba for cognitive impairment and dementia. The Cochrane database of systematic reviews: CD003120
  4. Bukstein, O (2008) Substance abuse in patients with attention-deficit/hyperactivity disorder. Medscape J Med 10: pp. 24
  5. Burgard, DA, Fuller, R, Becker, B, Ferrell, R, Dinglasan-Panlilio, MJ (2013) Potential trends in attention deficit hyperactivity disorder (adhd) drug use on a college campus: wastewater analysis of amphetamine and ritalinic acid. Sci Total Environ 450-51: pp. 242-249 CrossRef
  6. Cakic, V (2009) Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology. J Med Ethics 35: pp. 611-615 CrossRef
  7. Campbell, AA (1987) Randomized response technique. Science 236: pp. 1049 CrossRef
  8. Chatterjee A (2004) Cosmetic neurology: For physicians the future is now. The virtual mentor: VM 6
  9. Deutsche Angestelltenkrankenkasse (DAK) (2009) Gesundheitsreport 2009. Analyse der Arbeitsunf?higkeitsdaten. Schwerpunktthema Doping am Arbeitsplatz. DAK Forschung, IGES Institut GmbH. Berlin/Hamburg
  10. Dietz, P, Striegel, H, Franke, AG, Lieb, K, Simon, P, Ulrich, R (2013) Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy 33: pp. 44-50 CrossRef
  11. Fachinformation (2008) Coffeinum N 0,2?g. MERCK dura, Berlin
  12. Fachinformation (2013) Attentin 5?mg Tablette. Medice, Berlin
  13. Franke, AG, Bagusat, C, Dietz, P, Hoffmann, I, Simon, P, Ulrich, R, Lieb, K (2013) Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. BMC Med 11: pp. 102 CrossRef
  14. Franke, AG, Bonertz, C, Christmann, M, Huss, M, Fellgiebel, A, Hildt, E, Lieb, K (2011) Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in germany. Pharmacopsychiatry 44: pp. 60-66 CrossRef
  15. Franke, AG, Christmann, M, Bonertz, C, Fellgiebel, A, Huss, M, Lieb, K (2011) Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in germany. Pharmacopsychiatry 44: pp. 331-338 CrossRef
  16. Franke, AG, Heinrich, I, Lieb, K, Fellgiebel, A (2014) The use of ginkgo biloba in healthy elderly. Age 36: pp. 435-444 CrossRef
  17. Franke, AG, Lieb, K Pharmacological neuroenhancement: substances and epidemiology. In: Hildt, E, Franke, AG eds. (2013) Cognitive enhancement—an interdisciplinary perspective. Springer, Heidelberg, pp. 17-27
  18. Franke, AG, Lieb, K (2010) pharmacological neuroenhancement and brain doping: chances and risks. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53: pp. 853-859 CrossRef
  19. Franke, AG, Lieb, K, Fellgiebel, A (2009) from symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of alzheimer’s disease. Fortschr Neurol Psychiatr 77: pp. 326-333 CrossRef
  20. Franke AG, Bagusat C; McFarlane C, Tassone-Steiger T, Kneist W, Lieb K (2014) The use of caffeinated substances by surgeons for cognitive enhancement. Ann Surg [Epub ahead of print]
  21. Hart, CL, Haney, M, Vosburg,
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Psychiatry
  Neurosciences
  Neurology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-8491

文摘

Pharmacological “cognitive enhancement-(CE) is defined as the use of any psychoactive drug with the purpose of enhancing cognition, e.g. regarding attention, concentration or memory by healthy subjects. Substances commonly used as CE drugs can be categorized into three groups of drugs: (1) over-the-counter (OTC) drugs such as coffee, caffeinated drinks/energy drinks, caffeine tablets or Ginkgo biloba; (2) drugs being approved for the treatment of certain disorders and being misused for CE: drugs to treat attention-deficit/hyperactivity disorder (ADHD) such as the stimulants methylphenidate (MPH, e.g. Ritalin?) or amphetamines (AMPH, e.g. Attentin? or Adderall?), to treat sleep disorders such as modafinil or to treat Alzheimer’s disease such as acetylcholinesterase inhibitors; (3) illicit drugs such as illicit AMPH, e.g. “speed- ecstasy, methamphetamine (crystal meth) or others. Evidence from randomized placebo-controlled trials shows that the abovementioned substances have limited pro-cognitive effects as demonstrated, e.g. regarding increased attention, increased cognitive speed or shortening of reaction times, but on the same time poses considerable safety risks on the consumers. Prevalence rates for the use of CE drugs among healthy subjects show a broad range from less than 1?% up to more than 20?%. The range in prevalence rates estimates results from several factors which are chosen differently in the available survey studies: type of subjects (students, pupils, special professions, etc.), degree of anonymity in the survey (online, face-to-face, etc.), definition of CE and substances used/misused for CE, which are assessed (OTC drugs, prescription, illicit drugs) as well as time periods of use (e.g. ever, during the past year/month/week, etc.). A clear and comprehensive picture of the drugs used for CE by healthy subjects and their adverse events and safety risks as well as comprehensive and comparable international data on the prevalence rates of CE among healthy subjects are of paramount importance for informing policy makers and healthcare professionals about CE.